Administrative Core
行政核心
基本信息
- 批准号:10488238
- 负责人:
- 金额:$ 12.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-13 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAddressAdult GlioblastomaBioinformaticsBiologicalBiological MarkersBudgetsClinical TrialsCollaborationsCommunicationConflict (Psychology)DataData ProvenanceDeoxyguanosineDrug TargetingEnsureEvaluationExpenditureFosteringFundingFutureGlioblastomaGoalsGuidelinesInfrastructureInstitutionManuscriptsMediatingMonitorOccupational activity of managing financesOffice of Administrative ManagementPatientsPilot ProjectsPoliciesPreparationProcessProductivityProgram EvaluationPublicationsRegulationReportingResearchResearch PersonnelResearch SubjectsResource SharingResourcesScheduleScienceSiteSpecimenStructureTelomeraseTherapeuticTimeUnited States National Institutes of HealthUniversitiesVisitbiobankconflict resolutiondata integritydata managementearly phase clinical trialimmunogenicinnovationmeetingsnovelnovel strategiesoperationpatient populationpreclinical developmentprofessorquality assurancetelomere
项目摘要
PROJECT SUMMARY – Administrative Core
This Duke/UT Southwestern Glioblastoma Therapeutics Network (GTN) team will complete pre-clinical
development of a novel treatment for patients with glioblastoma (GBM) and investigate the biologic activity of
this agent in an early-phase clinical trial. In support of this goal, this Administrative Core is responsible for
overseeing, integrating, coordinating, and supporting Projects 1 and 2 and the shared Biomarker, Bioinformatics
and Biorepository Core. The Administrative Core will oversee the organizational infrastructure, integration of all
components, and carry out day-to-day administrative activities; serve as the liaison with all internal and external
constituencies; provide support for preparation of reports, manuscripts, and regulatory documents; and foster
team science by facilitating collaboration and smooth communication through regular meetings, seminars, and
other interactions. It will also provide fiscal management to ensure timely financial accounting and reporting
according to university and NIH policies; provide regulatory support to ensure compliance with institutional, state,
and federal research guidelines; oversee data operations to ensure use of best practices for data provenance
and integrity (e.g., monitoring standards such as SOPs, GCP); provide scientific management by monitoring
research progress/productivity and enable effective use of shared resource cores relative to scientific milestones
and budget milestones; conduct ongoing rigorous Program evaluations, with guidance and direction provided by
a Steering Committee and an Internal Advisory Board; resolve conflict; and delineate specific publication and
data distribution policies. Critically, this Core will also oversee interactions with other funded GTN U19 sites,
communication with Network Coordination Center, and the use of yearly trans-U19 Pilot Project Funds. This
Core is structured to reduce administrative burden, allowing investigators to focus on developing a novel
approach for treating adult GBM using an innovative telomerase-mediated telomere-targeting drug, 6-thio-2′-
deoxyguanosine (6-thio-dG), through high-quality, rigorous, and efficient research.
项目摘要 - 行政核心
这支公爵/UT西南胶质母细胞瘤治疗学网络(GTN)团队将完成临床前
开发针对胶质母细胞瘤(GBM)患者的新型治疗方法,并研究
该代理在早期临床试验中。为了支持这个目标,该行政核心负责
监督,集成,协调和支持项目1和2和共享的生物标志物,生物信息学
和生物座核。行政核心将监督组织基础架构
组件,并进行日常行政活动;充当所有内部和外部的联络
选区;为准备报告,手稿和监管文件提供支持;和福斯特
团队科学通过常规会议,半人选和平稳沟通来促进合作和平稳的沟通
其他互动。它还将提供财政管理,以确保及时的财务会计和报告
根据大学和NIH政策;提供监管支持,以确保遵守机构,国家,
和联邦研究指南;监督数据操作以确保最佳实践用于数据propeance
和完整性(例如,监视标准,例如SOP,GCP);通过监视提供科学管理
研究进度/生产力,并有效利用相对于科学里程碑的共享资源核心
和预算里程碑;进行持续严格的计划评估,并提供指导和指导
指导委员会和内部顾问委员会;解决冲突;并描述特定的出版物和
数据分配策略。至关重要的是,该核心也将与其他资助的GTN U19站点进行海外互动,
与网络协调中心的沟通,以及使用年度Trans-U19试点项目基金的使用。这
核心的结构是减少行政燃烧,使调查人员能够专注于开发小说
使用创新的端粒介导的端粒药物治疗成人GBM的方法,6-THIO-2'--
通过高质量,严格且有效的研究,脱氧鸟苷(6- thio-dg)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M. Ashley其他文献
Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas.
卡铂 (CBDCA) 在进行性低级别胶质瘤中的 II 期研究。
- DOI:
- 发表时间:
1998 - 期刊:
- 影响因子:4.1
- 作者:
Albert Moghrabi;Henry S Friedman;David M. Ashley;K. Bottom;T. Kerby;Elizabeth A. Stewart;Carol S. Bruggers;James M. Provenzale;Martin A. Champagne;Linda Hershon;M. Watral;Janis Ryan;Karima Rasheed;Shelley Lovell;David N. Korones;Herbert E. Fuchs;Timothy M George;R. McLendon;A. Friedman;Edward G. Buckley;D. Longee - 通讯作者:
D. Longee
The evolution of the histology in pleomorphic xanthoastrocytomas in children: a study of 15 cases
儿童多形性黄色星形细胞瘤15例组织学演变
- DOI:
10.1097/pat.0b013e328340bb98 - 发表时间:
2011 - 期刊:
- 影响因子:4.5
- 作者:
Xiangru Wu;P. Bandopadhayay;J. Ng;David M. Ashley;C. Chow - 通讯作者:
C. Chow
General anaesthesia or conscious sedation for painful procedures in childhood cancer: the family‘s perspective
全身麻醉或清醒镇静治疗儿童癌症的痛苦手术:家人的观点
- DOI:
10.1136/adc.88.3.253 - 发表时间:
2003 - 期刊:
- 影响因子:5.2
- 作者:
C. Crock;C. Olsson;R. Phillips;G. Chalkiadis;S. Sawyer;David M. Ashley;S. Camilleri;J. Carlin;P. Monagle - 通讯作者:
P. Monagle
Brain stem gliomas: Patterns of Care in Victoria from 1998–2000
- DOI:
10.1016/j.jocn.2007.04.008 - 发表时间:
2008-03-01 - 期刊:
- 影响因子:
- 作者:
Mark A. Rosenthal;David M. Ashley;Katharine J. Drummond;Michael Dally;Michael Murphy;Lawrence Cher;Vicky Thursfield;Graham G. Giles - 通讯作者:
Graham G. Giles
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma
STING 激动剂 8803 重新编程免疫微环境并提高胶质母细胞瘤临床前模型的存活率
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:15.9
- 作者:
Hinda Najem;S. Lea;Shashwat Tripathi;Lisa Hurley;Chao;Ivana William;Moloud Sooreshjani;Michelle Bowie;Genevieve Hartley;Corey Dussold;Sebastian Pacheco;C. Dmello;Catalina Lee;Kathleen McCortney;Alicia Steffens;Jordain Walshon;Martina Ott;Jun Wei;Anantha L. Marisetty;I. Balyasnikova;R. Stupp;R. Lukas;Jian Hu;C. D. James;C. Horbinski;Maciej S. Lesniak;David M. Ashley;Waldemar Priebe;Leonidas C. Platanias;Michael A. Curran;Amy B. Heimberger - 通讯作者:
Amy B. Heimberger
David M. Ashley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M. Ashley', 18)}}的其他基金
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
ATRX 突变、先天免疫激活和恶性胶质瘤的治疗脆弱性
- 批准号:
10375084 - 财政年份:2022
- 资助金额:
$ 12.35万 - 项目类别:
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
ATRX 突变、先天免疫激活和恶性胶质瘤的治疗脆弱性
- 批准号:
10666347 - 财政年份:2022
- 资助金额:
$ 12.35万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
- 批准号:
10488242 - 财政年份:2021
- 资助金额:
$ 12.35万 - 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
- 批准号:
10488237 - 财政年份:2021
- 资助金额:
$ 12.35万 - 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
- 批准号:
10305565 - 财政年份:2021
- 资助金额:
$ 12.35万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
- 批准号:
10305568 - 财政年份:2021
- 资助金额:
$ 12.35万 - 项目类别:
Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma?
低肿瘤突变负荷是否可以预测复发性胶质母细胞瘤对溶瘤脊髓灰质炎病毒治疗的反应?
- 批准号:
9807277 - 财政年份:2019
- 资助金额:
$ 12.35万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Towards the automation of MR spectroscopic imaging in patients with glioblashoma
胶质母细胞瘤患者磁共振波谱成像的自动化
- 批准号:
9191930 - 财政年份:2016
- 资助金额:
$ 12.35万 - 项目类别:
Development of Transporter Targeted Platinum Drugs for Glioblastoma
胶质母细胞瘤转运蛋白靶向铂类药物的开发
- 批准号:
9134555 - 财政年份:2016
- 资助金额:
$ 12.35万 - 项目类别: